The Brooks Group

DECEMBER 19, 2008

Recently, I was having a conversation with a client who mentioned that, even in our current economy, his top salespeople were still leading the pack! They were doing so with numbers a bit lower than the previous year. In actuality, everyone's numbers had dropped across the board, although some drops were more severe than others. The client went on to explain that some fluctuation was to be expected, and discussed how important it would be to make sure that next year's goals would be realistic fo

Prospecting 40

Prospecting Leads 40

Pharmaceutical Technology

OCTOBER 5, 2008

Outward M&A growth is unusual territory for Japan. But the recent acquisition by Japanese pharmaceutical provider Shionogi of US-based rival Sciele Pharma, worth $1,276m, is just the latest in a spree of big and bold outbound deals. It seems the most valuable deals have been with Western companies, according to the latest statistics from Dealogic.

Government 52

Government Marketing Pharmaceutical Physicians 52

The Brooks Group

DECEMBER 18, 2008

I joined The Brooks Group just over a month ago and I thought it would be apropos to offer some tips or reminders on hiring and potentially bringing on a new associate. Pre employment: 1. The 80/20 rule should apply when it comes to who is doing the talking. Try and ask open-ended questions to ensure the candidate does most of the talking. 2. While the candidate impressing you is most important, keep in mind that you should sell the company to the candidate as well.

Prospecting 40

Prospecting Sales 40

Pharmaceutical Technology

SEPTEMBER 10, 2008

Natalie Coomber: Can you provide a quick background on the history of Biotest and the main work it is currently undertaking? Dr Ivana Surovà: Biotest s.r.o. was established in 1999 in the process of privatisation of the State Research Institute for Pharmacy and Biochemistry in the Czech Republic. Before the inception of this institute, the facility was oriented towards pre-clinical toxicology and breeding of the laboratory animals.

Food and Drug Administration 52

Food and Drug Administration Education Recruitment Training 52

Advertisement

Distribution

Pharmaceutical Technology

AUGUST 26, 2008

It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceutical companies have made increasing use of biotechnology in discovering and manufacturing new medicines. According to Nick Staples, director of corporate affairs for pharmaceutical company Protherics, it is in its impressive variety that biotechnology holds such promise for the pharma

Manufacturing 52

Manufacturing Pharmaceutical Biopharma Medicine 52

Pharmaceutical Technology

AUGUST 17, 2008

Nicola Boyes: The FDA has come under criticism recently for extreme delays in approving new drugs for the market, is the criticism valid and if so how are the delays impacting on the US pharmaceutical industry at present? Dr Alan S Louie: I think the question is actually somewhat more complicated than that. Yes there has been some slowing in the approval of drugs from the FDA, in part due to legitimate concerns in relation to drug safety.

Food and Drug Administration 52

Food and Drug Administration Food FDA Safety 52

Pharmaceutical Technology

JUNE 22, 2008

Pharmaceutical companies dealing with the US will be closely watching the debate surrounding a proposed revision by the Senate which could see the watering down of some requirements, and an increase in others, under its Physician Payments Sunshine Act (S.2029). The bill mostly relates to pharmaceutical companies, and the new amendments due to come in place in 2011 could impose further regulation.

Physicians 52

Physicians Doctors Pharmaceutical Consulting 52

The Brooks Group

JANUARY 2, 2008

Can't it be hard to get appointments with prospects? We've all had the experience of leaving phone messages, or networking at events, for prospects we are fairly sure are good ones. I can't give you the magic tool that will make every prospect call back - or accept your next call - but I can make a suggestion that will improve your odds significantly.

Prospecting 40

Prospecting Sales Management Networking Sales 40

Pharmaceutical Technology

MAY 11, 2008

Pharmaceutical companies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up. As a result, governments are eager to protect patients from counterfeit medication, save on the costs of fraud and introduce regulatory systems throughout the drug supply chain which can afford full accountability right back to the production facility.

Electronics 52

Electronics Transportation Pharmaceutical manufacturing Pharmaceutical 52

Pharmaceutical Technology

JULY 23, 2008

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler. “And ther

Side effects 52

Side effects Marketing Pharmaceutical Sales 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Pharmaceutical Technology

MAY 29, 2008

Andrew Witty took the helm of pharmaceutical giant GlaxoSmithKline in May 2008. At 43 he joins the ranks of a growing number of young chief executives in the pharmaceutical industry. Pharmaceutical-Technology spoke to Paul Diggle, analyst at Nomura Code Securities about Witty’s appointment. Pharmaceutical Technology: What do you think Andrew Witty’s appointment means for GlaxoSmithKline?

Pharmaceutical 52

Pharmaceutical Marketing Sales Prescription 52